Status | Study |
Completed |
Study Name: Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload Condition: Transfusional Iron Overload Beta-thalassemia Date: 2010-08-19 Interventions: Drug: SPD602 (FBS0701, SSP-004184) Oral FBS0701 taken one time daily for up to 96 weeks. |
Completed |
Study Name: A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity Condition: Transfusional Iron Overload Date: 2010-01-05 Interventions: Drug: ICL670 |
Completed |
Study Name: Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload Condition: Transfusional Iron Overload Beta-thalassemia Date: 2009-12-23 Interventions: Drug: FBS0701 Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg |
Completed |
Study Name: Iron Overload in Pediatric Oncology Patients Condition: Iron Overload Date: 2009-12-16 |
Completed |
Study Name: Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study Condition: Liver Iron Overload Date: 2009-10-16 Interventions: Drug: Deferasirox 10 mg/kg or |
Completed |
Study Name: Iron Overload in Stem Cell Transplant Recipients Condition: Iron Overload Date: 2008-12-10 |
Completed |
Study Name: Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload Condition: Iron Overload Date: 2008-04-02 Interventions: Drug: Deferasirox Other Name: ICL670 |
Completed |
Study Name: MRI Evaluation of Iron Overload in the Heart, Liver and Pancreas in Patients Receiving Multiple Blood Transfusions. Condition: Iron Overload Date: 2008-02-25 |
Completed |
Study Name: Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload Condition: Transfusional Iron Overload Transfusional Hemosiderosis Date: 2008-01-14 Interventions: Drug: Core Study: Deferasirox |
Completed |
Study Name: Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis Condition: Iron Overload Hereditary Hemochromatosis Date: 2006-11-01 Interventions: Drug: Deferasirox (ICL670) |